Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,646 total articles
Adam C Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, sold 27,083 shares on March 2, 2026, for $5.117 per share, netting $138,583. The transaction follows a conversion of restricted and performance stock units on February 27, 2026, and comes as the stock has risen almost 10% over the prior week but remains down about 45% year-ove…
Allegro Microsystems SVP and Chief Human Resources Officer Erin Hagen reported two recent sales of company stock in late February and early March 2026, collectively totaling $163,724. The moves coincide with a period of notable share-price gains for the semiconductor firm and come amid recent earnings outperformance, analyst target increases, a new…
Will W Anthony, former president and CEO of CF Industries Holdings, Inc. (NYSE: CF), sold a total of 255,962 shares of the company’s common stock in transactions on February 27 and March 2, 2026, totaling roughly $24.3 million. The sales were executed at prices spanning weighted averages from $99.0635 to $107.0377. Concurrently, Anthony received a …
Huron Consulting Group director John McCartney executed an automatic sale of 500 shares on March 2, 2026, for $69,575 under a Rule 10b5-1 plan. The stock has climbed to $148.46 since the sale. The company posted better-than-expected fourth-quarter adjusted EPS and revenue growth led by healthcare and commercial segments, though shares slipped after…
Expeditors International of Washington President and CEO Daniel R. Wall sold 6,100 shares on February 27, 2026, for $884,927. The transaction comes after the company reported fourth-quarter 2025 adjusted EPS of $1.49 on $2.86 billion in revenue and amid a new $3 billion share repurchase authorization. Analysts' price targets vary following the quar…
Guidewire Software Chief Executive Officer Michael George Rosenbaum sold 1,200 shares on March 2, 2026, under a pre-arranged trading plan. The transaction, worth $172,644, follows recent analyst support and the company’s announcement of a new $500 million share repurchase program. At current market prices, third-party analysis flags the stock as ov…
Myriam Curet, Executive Vice President and Chief Medical Officer at Intuitive Surgical Inc (ISRG), sold 4,853 shares on March 2 and 3, 2026, realizing roughly $2.36 million. The transactions occurred under a 10b5-1 trading plan that expires July 29, 2026. On March 2 she also exercised 125 non-qualified options at $208.90 each. Intuitive Surgical re…
USANA Health Sciences Chief Information Officer Benedict Peter sold 4,553 shares of company stock on March 3, 2026, in a transaction totaling $88,258. The company separately adjusted its 2025 net sales outlook slightly higher and released an initial revenue range for 2026 that spans $925 million to $1 billion. USANA also renewed its sponsorship agr…
Meta Platforms Chief Financial Officer Susan J. Li, acting through the Li-Hegeman Family Foundation, sold 55,571 shares of Class A common stock on February 27, 2026, for roughly $36.4 million. The trades were carried out under a 10b5-1 plan adopted November 25, 2025, with execution prices between $640.1058 and $648.8273 per share. The sale leaves t…
AppTech Payments Corp. director Albert L. Lord acquired a total of 100,000 common shares in two separate transactions worth $31,350. The purchases were executed on February 27 and March 2, 2026. Separately, the company filed an amendment to a $360,000 Senior Unsecured Convertible Promissory Note that resets maturity and staggers principal payments,…
Synchrony Financial Executive Vice President and CEO - Digital Bart Schaller executed a scheduled sale of 12,980 shares on March 2, 2026, under a Rule 10b5-1 plan, generating $878875. Separately, 14,610 restricted stock units vested on March 1, 2026, valued at $1009697, with 9,895 shares withheld to satisfy related taxes. After these movements Scha…
An executive at Synchrony Financial disposed of roughly $294,000 in common stock this week under a pre-established trading plan, while also receiving restricted stock units that will vest over three years. The company reported fourth-quarter 2025 earnings that matched earnings-per-share expectations but missed revenue targets, and announced partner…
Juel Carol, Executive Vice President and Chief Technology and Operating Officer at Synchrony Financial (NYSE:SYF), executed an open-market sale of 16,859 shares on March 2, 2026 for about $1.14 million and, a day earlier, received a grant of 24,093 restricted stock units valued at $1,665,067. Tax withholding of 14,561 shares reduced the net impact …
Netflix director Reed Hastings completed the sale of 410,650 common shares on March 2, 2026, generating about $39.8 million through multiple trades priced between $96.0572 and $97.5869. On the same day he exercised options to buy 410,550 shares at $9.667 each. Following these moves, Hastings holds a small direct stake and a substantial indirect pos…
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported an insider sale by Executive Vice President and Chief Quality Operations Officer John Richard Pinion, who sold 10,029 shares on March 2, 2026, for roughly $228,661. The transaction followed the conversion of performance stock units into common shares the prior day and leaves Pinion with 110,026…
Trupanion Chief Operating Officer John R. Gallagher sold 5,283 shares on February 27, 2026, for about $140,080 under a pre-arranged Rule 10b5-1 plan. The stock trades near a 52-week low after a six-month decline. The company reported fourth-quarter 2025 results that beat revenue estimates but missed on earnings per share, and InvestingPro analysis …
Neville Everett, an officer at Cigna Group (CI), sold 1,719 shares on March 2, 2026, under a Rule 10b5-1 plan adopted May 22, 2025, for $288.91 per share, totaling $496,636. Separately, on February 27, 2026, Everett completed several other equity-related actions including zero-value acquisitions, tax-related dispositions, and the grant of options t…
Elizabeth C. Cushman, Abbott Laboratories' Executive Vice President, General Counsel and Secretary, completed two sales of Abbott common stock in late February and early March 2026 totaling $195,602. After the transactions she holds 38,573 shares. Abbott continues to declare dividends, report positive clinical outcomes for an atrial fibrillation th…
Robert P. Goodman, a director at CS Disco, Inc. (NASDAQ: LAW), purchased 1,026,700 shares on February 27, 2026, in a transaction valued at $3,275,173. The purchase occurred at prices between $3.10 and $3.19. Following the trade, Goodman’s direct and indirect holdings are disclosed. CS Disco recently reported fourth-quarter 2025 results that beat an…
Reddit CEO Steve Huffman sold 17,900 shares of Class A common stock on February 27, 2026, in multiple trades totaling about $2.6 million. The trades were carried out under a pre-arranged Rule 10b5-1 plan adopted May 19, 2025. On the same day Huffman exercised options to acquire 18,000 Class A shares at a price of $0.00 per share; those options were…
Atomera Inc. (NASDAQ: ATOM) Chief Technology Officer Robert J. Mears sold 3,989 shares on March 2, 2026, while simultaneously receiving substantial equity awards at no cost. The move coincides with the company’s recent registered direct offering, a fourth-quarter 2025 earnings report that met EPS expectations but showed weak revenue, and share-pric…
Atomera Inc.'s chief financial officer, Francis Laurencio, sold 4,799 shares on March 2, 2026, for $4.95 per share, generating $23,755 in proceeds. The transaction coincided with the stock trading below its prior close, despite the equity being up 117% year-to-date. A Form 4 filing also shows Laurencio received 114,504 shares through performance an…
Acumen Pharmaceuticals Chief Legal Officer Derek M. Meisner sold 9,406 shares of common stock on February 27, 2026 under a pre-arranged Rule 10b5-1 plan and exercised options to buy the same number of shares the same day. The sale generated about $28,311 at a weighted average price of $3.0099, while the option exercise paid $1.85 per share for a to…
Mark A. Goldsmith, a director at Revolution Medicines (RVMD), sold common shares totaling $3,644,353 on March 2, 2026, and executed option activity across March 1-2. The company recently reported a wider fourth-quarter 2025 loss driven by higher R&D and SG&A spend, while several analysts revised coverage and price targets.
Arlo Technologies' Chief Financial Officer, Kurtis Joseph Binder, sold 12,539 shares on March 3, 2026, realizing $187,183 at a weighted average price of $14.9281. The transaction, disclosed on a Form 4 filed with the SEC, reduced Binder's direct holdings to 470,635 shares. The sale occurred after the stock climbed 27% during the prior week and ahea…
